To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
|ClinicalTrials.gov Identifier: NCT01420328|
Recruitment Status : Unknown
Verified December 2012 by Paresh Dandona, MD, Kaleida Health.
Recruitment status was: Active, not recruiting
First Posted : August 19, 2011
Last Update Posted : December 18, 2012
Information provided by (Responsible Party):
Paresh Dandona, MD, Kaleida Health
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ghanim H, Green K, Abuaysheh S, Patel R, Batra M, Chaudhuri A, Makdissi A, Kuhadiya ND, Dandona P. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis. 2017 Aug;263:278-286. doi: 10.1016/j.atherosclerosis.2017.06.010. Epub 2017 Jun 7.